The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy

Metabolism: Clinical and Experimental

Volumn 49, Issue 8, 2000, Pages 1030-1035

  Shimoike, T ^a   Inoguchi, T ^a   Umeda, F ^a   Nawata, H ^a   Kawano, K ^a   Ochi, H ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; CREATININE; GLUCOSE; HEMOGLOBIN A1C; MALONALDEHYDE;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; FEMALE; GLUCONEOGENESIS; GLYCOSYLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEINURIA; URINE LEVEL;

EID: 0033886339     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2000.7738     Document Type: Article

References (33)

1. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
2. Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging
3. Advanced protein glycosylation in diabetes and aging
4. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence
5. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM
6. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus
7. Immunochemical detection of advanced glycosylation end products in vivo
8. Immunochemical detection of advanced glycation end products in lens crystallins from streptozocin-induced diabetic rat
9. Immunochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat
10. Production and characterization of antibodies to advanced glycation products on proteins
11. Immunochemical approach to characterize advanced glycation end products of the Maillard reaction
12. Advanced glycosylation end products in patients with diabetic nephropathy
13. Reactive glycosylation endproducts in diabetic uremia and treatment of renal failure
14. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD
15. Immunological determination of advanced glycosylation end-products in human blood and urine
16. Increased serum levels of advanced glycation end-products and diabetic complications
17. Pathophysiology of advanced glycation end-products in renal failure
18. Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients
19. Urinary 8-hydroxy-2'-deoxyguanosine as a biological marker of in vivo oxidative DNA damage
20. Quantitative immunohistochemical determination of 8-hydroxy-2'-deoxyguanosine by a monoclonal antibody N45.1: Its application to ferric nitrilotriacetate-induced renal carcinogenesis model
21. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus
22. The effect of intensive treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus
23. Reversal of glomerular hyperfiltration and hypertrophy by blood glucose normalization in diabetic rats
24. ECM gene expression and its modulation by insulin in diabetic rats
25. Glucose control suppressed the glomerular expression of TGF-β1 and the progression of experimental diabetic nephropathy
26. Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy
27. Identification of Nξ-(carboxymethyl)lysine (CML) as a degradation product of fructose lysine in glycated protein
28. Reaction of ascorbate with lysine and protein under autoxidizing conditions: Formation of Nξ-(carboxymethyl)lysine (CML) by reaction between lysine and products of autoxidation of ascorbate
29. Mechanism of autoxidative glycosylation: Identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose
30. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure
31. New biomarker evidence of oxidative DNA damage in patients with non-insulin-dependent diabetes mellitus
32. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus
33. Advanced glycation end-products in diabetic nephropathy